In Brief: Neopath
This article was originally published in The Gray Sheet
Executive Summary
Neopath: Investigating complementing its AutoPap 300 automated Pap smear analyzer system with Cambridge, Massachusetts-based CompuCyte Corporation's Pathfinder cytology system, which it has purchased for $5 mil. in cash and stock. The Pathfinder, which consists of a microprocessor-controlled microscope capable of recording data on screened areas, will continue to be sold as a stand-alone product while NeoPath investigates using it to "guide the cytotechnologist to suspicious cells identified by the AutoPap," the firm says in a release...
You may also be interested in...
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.